Danish Observational Study of Everolimus Plus Exemestane in Hormone Receptor (HR) Positive, Human Epidermal Growth Factor 2 (HER2) - Metastatic Breast Cancer

Inclusion Criteria: * Postmenopausal women with HR-positive, HER2-negative advanced breast cancer who are treated with everolimus and exemestane according to the approved Summary of Product Characteristics (SmPC). * Patients who started treatment after approval of this indication but before the initiation of this study can be retrospectively included, provided that they have systematically been assessed for adverse events. * The decision to treat the patient with everolimus and exemestane must be independent of the patient's participation in the study. * The patient must provide signed Informed Consent before any data can be captured. Exclusion Criteria: \- No formal exclusion criteria